UPDATE: FDA Grants Orphan Drug Status to Metadoxine in Fragile X Syndrome

Alcobra (Nasdaq: ADHD ) announced today that the U.S. Food & Drug Administration has granted "Orphan Drug" designation to Metadoxine in the treatment of Fragile X Syndrome. The Orphan Drug Act (ODA) provides for granting special status to a drug or biological product to treat a rare disease